combination of cognitive behavioral therapy and medication in treatment of schizophrenia

The effectivness of cognitive behavioral therapy in combination with Pharmacotherapy on symptom control and quality of life in patients with schizophreneia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016110627691N2

Enrollment

Registered

2017-04-07

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Cognitive behavioral therapy for patients with schizophrenia , 14 to16 sessions (2 sessions per week) individually ,according to Nicola wright protocol.

Rehabilitation

Cognitive behavioral therapy for patients with schizophrenia , 14 to16 sessions (2 sessions per week) individually ,according to Nicola wright protocol

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with schizophrenia disorder according to DSM- IV -TR classificationand interview ; age between 20 to 50 ? at least 8 classes education; Patients will enrolled in the study only after obtaining informed consent; CBT will be the only psychosocial intervention which will be provided to these patients. Exclusion criteria:, with at least 8 classes education;Patients with any history of substance abuse ;.patients with any history of neurological or medical disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Positive symptoms. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: positive and negative syndrome scale.;Negative symptoms. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: positive and negative syndrome scale.	—

Measure

Time frame

Positive symptoms. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: positive and negative syndrome scale.;Negative symptoms. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: positive and negative syndrome scale.

—

Secondary

Measure	Time frame
Quality of life. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: World Health organizatin-Quality of life.;Insight. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: Insight scale.;Global functional patients. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: Global Assessment of functioning scale.	—

Measure

Time frame

Quality of life. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: World Health organizatin-Quality of life.;Insight. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: Insight scale.;Global functional patients. Timepoint: at the first and after termination of cognitive behavioral therapy sessions and 12 weeks after the last sessions. Method of measurement: Global Assessment of functioning scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Mirsepassi

Roozbeh Hospital

zahesbanoo@yahoo.com z-mirsepassi@sina-tums.ac.ir+98 21 5541 4084

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026